Big Pharma Drags Its Feet on Modernizing Clinical Trial Monitoring

Despite moving most operations in-house—from budgeting and data analysis to biostatistics—major pharmaceutical companies continue to rely on an outdated outsourcing model for site monitoring. They persist with functional service provider arrangements, paying for on-site monitoring even though modern technology could streamline these processes. This reveals a stubborn disconnect between traditional practices and the efficiencies available in today's clinical trial management.